TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come – Seeking Alpha
|
TiGenix: This Stem Cell Pioneer Is Up 40% Since IPO With More Upside To Come
Seeking Alpha The biotech has signed a $400+ million deal with big pharma Takeda for its lead asset, Cx601, which should be approved in Europe before YE2017. TiGenix still owns 100% of US rights to Cx601, which represents a larger market opportunity than Europe and … |
